* AB SCIENCE *
2001 - IDF
Paris
www.ab-science.com Discovery, Drugs
Key words: Mastocytosis, Inhibitors, Tyrosine Kinase, Anticancer, Inflammation, Auto-immune diseases
Mission: to develop innovative tyrosine kinase inhibitors for auto-immune diseases in man and animals
Clients: Prescribers, Veterinarians
ines.delov@ab-science.com
Identity| TYPE/MANAGEMENT/INVESTORS | FINANCES/STATUS | | Start-up |
Managing Dir.: Moussy (Alain) [founder, born 1965, MBA Wharton, ENSTA, ex-Carrefour (Dir M&A)]
Sc.Dir.:
Fin.Dir.: Guy (Laurent)
BusDev:
Financers: privately owned | Turnover (M€) : n.a.
Total funding (M€) : 30.0
Last funding (M€) : n.a.
Focus : Cancers
Position : Clinical
Company confirm : neutral |
History | DATE | MILESTONE | TYPE | TIME | | 2008 .09 | Registration : positive opinion from EMEA for lead compound masitinib in the treatment of canine mast cell tumor | MKTG | [7 years] |
| 2007 .05 | Court : legal prosecution against Medicen, Paris Pôle de Compétitivité, with a claim of 125 M€ | LEGAL | [6 years] |
| 2001 .07 | Company founded by Alain Moussy | ORGF | [0 year] | Actualisation / Updating: 31-Oct-2008 |
|
